Company intelligence / Profile preview

Guangdong Hengrui Pharmaceutical Co., Ltd

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Hengrui has over 24 innovative drugs commercialized in China, more than 100 innovative pipeline assets, and global partnerships enabling both independently developed and partnered assets to advance through clinical stages and approvals worldwide; recent approvals include recaticimab for hypercholesterolemia and robust phase 2/3 programs in autoimmune and respiratory diseases

Therapeutic areas: ImmunologyDermatologyCardiovascularPulmonology
Modalities: Monoclonal antibodySmall moleculeBiological productsFab fragmentFusion proteinAntibody-drug conjugateRadioligand therapy
Industry: Pharma

Partnerships

GSK (12-program partnership across respiratory, immunology & oncology)Merck & Co. (previous co-development/licensing)

Beyond the preview

Go deeper on Guangdong Hengrui Pharmaceutical Co., Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangdong Hengrui Pharmaceutical Co., Ltd.

Explore the full profile